View Older Stories View More Recent Stories

Dec 14, 2023 04:31PM Cullinan Oncology (CGEM) Doses First Patient in Phase 1 Trial of CLN-617
Dec 14, 2023 04:30PM Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Nov 8, 2023 07:00AM Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Nov 3, 2023 12:01PM Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
Oct 30, 2023 08:00AM Cullinan Oncology to Participate in Upcoming Investor Conferences
Sep 6, 2023 08:00AM Cullinan Oncology to Participate in Upcoming Investor Conferences
Aug 10, 2023 07:00AM Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Aug 9, 2023 07:00AM Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Aug 3, 2023 04:15PM REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Jul 31, 2023 08:00AM Cullinan Oncology to Participate in Upcoming Investor Conferences
May 25, 2023 05:00PM Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 11, 2023 04:01PM Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
Apr 26, 2023 10:08AM Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
Apr 26, 2023 10:08AM Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
Apr 20, 2023 07:00AM Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
Apr 20, 2023 07:00AM Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
Mar 27, 2023 07:02AM Cullinan Oncology (CGEM) Announces FDA Clearance of Investigational NDA for CLN-617
Mar 27, 2023 07:00AM Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
Mar 27, 2023 07:00AM Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
Mar 14, 2023 04:35PM Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
Mar 14, 2023 04:35PM Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
Mar 9, 2023 07:00AM Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 9, 2023 07:00AM Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 27, 2023 08:00AM Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
Feb 27, 2023 08:00AM Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
Feb 14, 2023 05:44AM Cullinan Oncology (CGEM) Licenses US Rights to HBM7008 from Harbour BioMed
Feb 13, 2023 07:00PM Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
Feb 13, 2023 07:00PM Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
Feb 2, 2023 04:01PM Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
Feb 2, 2023 04:01PM Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
Feb 1, 2023 04:41PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1, 2023 04:41PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 24, 2023 08:00AM Cullinan Oncology (CGEM) Granted FDA Clearance of iNDA for CLN-978
Jan 24, 2023 08:00AM Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Jan 24, 2023 08:00AM Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Jan 3, 2023 05:13PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 3, 2023 05:13PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 2, 2022 05:00PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 2, 2022 05:00PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 14, 2022 07:00AM Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Nov 14, 2022 07:00AM Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Nov 2, 2022 08:00AM Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
Nov 2, 2022 08:00AM Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors
Nov 1, 2022 05:23PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 1, 2022 05:23PM Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 1, 2022 07:00AM Cullinan Oncology to Participate in Upcoming Investor Conferences
Nov 1, 2022 07:00AM Cullinan Oncology to Participate in Upcoming Investor Conferences
Oct 25, 2022 07:03AM Cullinan Oncology (CGEM) Boosts Ownership Stake in its MICA Subsidiary
Oct 25, 2022 07:00AM Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
Oct 25, 2022 07:00AM Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619
View More Recent Stories View Older Stories